Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.83 - $3.53
Previous Close$1.96
Volume269.01K
Average Volume (3M)1.05M
Market Cap
$70.11M
Enterprise Value$118.88M
Total Cash (Recent Filing)$22.29M
Total Debt (Recent Filing)$61.72M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 18, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding72,193,770
10 Day Avg. Volume700,806
30 Day Avg. Volume1,050,070
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue6.99K
Enterprise Value/Gross Profit-216.14
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$6.53Price Target Upside566.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe Germany Real-World Registry study showed a median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure, with no serious adverse events.
Clinical Trial Results3-month data from the open-label cohort of the pivotal trial surprised to the upside and suggests a likely positive outcome.
Financial PositionA recent offering completed in August raised approximately $23M, with additional potential proceeds from warrants, extending cash runway into 2026.
Bears Say
Gene Therapy RisksConcerns exist regarding the potential risks and complexities associated with GLP-1 gene therapy, including the need for advanced procedural training and the dangers of pancreatic injections.
Skepticism And UncertaintyThere is skepticism over the unclear mechanism of duodenal resurfacing, though some believe it works based on existing data.
Stock Price TargetThe price target was decreased to $6 from a previous $12, following the updates in the model for 2Q25 results.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.82 and its highest was $3.53 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $70.11M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 75 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.2.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 72,193,770 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went up 3.061%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.53 (566.33% Upside)
$6.53 (566.33% Upside)
Hedge Fund Trend
Decreased
By 21.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.11%
12-Months-Change
Fundamentals
Return on Equity
-379.75%
Trailing 12-Months
Asset Growth
-57.66%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Fractyl Health's earnings call highlighted several positive developments, including a strengthened financial position, strategic focus on reducing cash burn, and promising data from the Revita program. However, the company also reported an increased net loss and highlighted dependence on future data readouts for continued success. The overall sentiment is cautiously optimistic, with significant potential contingent on upcoming results.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$6.53
▲(566.33% Upside)
Technical Analysis
Immucell
―
PDS Biotechnology
―
CytomX Therapeutics
―
Cue Biopharma
―
PMV Pharmaceuticals
―
Ownership Overview
18.83% Insiders
3.69% Mutual Funds
31.92% Other Institutional Investors
43.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---